Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles from Sweden
Based on 457 articles published since 2009
||||

These are the 457 published articles about Coronary Artery Disease that originated from Sweden during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19
1 Editorial Paclitaxel Eluting Endovascular Technology and Long-Term Mortality: Safety Concern or a Reminder of an Obvious Literature Gap? 2019

Saratzis, Athanasios / Mani, Kevin / Zayed, Hany. ·Department of Vascular Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: as875@le.ac.uk. · Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. · Department of Vascular Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK. ·Eur J Vasc Endovasc Surg · Pubmed #30773410.

ABSTRACT: -- No abstract --

2 Editorial Coronary Artery Disease in Systemic Lupus Erythematosus. 2018

Nilsson, Jan. ·Department of Clinical Sciences Malmö Lund University, Lund, Sweden. Electronic address: jan.nilsson@med.lu.se. ·Am J Med Sci · Pubmed #30384949.

ABSTRACT: -- No abstract --

3 Editorial Lung Function and Coronary Artery Disease Risk. 2018

Nowak, Christoph. ·Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Huddinge, Sweden. christoph.nowak@ki.se. ·Circ Genom Precis Med · Pubmed #29650768.

ABSTRACT: -- No abstract --

4 Editorial Coronary Artery Disease and Its Risk Factors: Leveraging Shared Genetics to Discover Novel Biology. 2016

Quertermous, Thomas / Ingelsson, Erik. ·From the Division of Cardiovascular Medicine, Department of Medicine (T.Q., E.I.), Cardiovascular Institute (T.Q., E.I.), Stanford University School of Medicine, CA · and Molecular Epidemiology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden (E.I.). ·Circ Res · Pubmed #26837740.

ABSTRACT: -- No abstract --

5 Editorial Regulatory T cells: getting to the heart of the matter. 2016

Nilsson, J. ·Department of Clinical Sciences, Lund University, Malmö, Sweden. ·J Intern Med · Pubmed #26514991.

ABSTRACT: -- No abstract --

6 Editorial Serum S100A12: A Risk Marker or Risk Factor of Vascular Calcification in Chronic Kidney Disease. 2015

Lindholm, Bengt. ·Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. ·Am J Nephrol · Pubmed #26278719.

ABSTRACT: -- No abstract --

7 Editorial Obstructive sleep apnoea and cardiovascular calcification. 2015

Bäck, Magnus / Stanke-Labesque, Françoise. ·Translational Cardiology, Karolinska Institutet, Stockholm, Sweden Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden. · Université Grenoble Alpes, Grenoble, France INSERM U1042, HP2,Grenoble, France Department of Pharmacology, CHU, Grenoble, France. ·Thorax · Pubmed #26272928.

ABSTRACT: -- No abstract --

8 Editorial Women with nonobstructive coronary artery disease are not necessarily healthy. 2015

Schenck-Gustafsson, Karin / Johnston, Nina. ·1 Department of Cardiology Centre for Gender Medicine, Karolinska University Hospital , Stockholm, Sweden . ·J Womens Health (Larchmt) · Pubmed #25973797.

ABSTRACT: -- No abstract --

9 Editorial Recognition of resting heart calcification as a means to an end: an eye-opener in the application of dobutamine stress echocardiography in subjects with chest pain. 2015

Saha, Samir K / Govind, Satish C. ·Karolinska Institutet, Sundsvall, Sweden. · Narayana Institute of Cardiac Sciences, Bangalore, India. ·Echocardiography · Pubmed #25728209.

ABSTRACT: -- No abstract --

10 Editorial Computerized decision making in myocardial perfusion SPECT: The new era in nuclear cardiology? 2015

Trägårdh, Elin / Carlsson, Marcus / Edenbrandt, Lars. ·Clinical Physiology and Nuclear Medicine, Lund University, Skåne University Hospital, Malmö, Sweden. elin.tragardh@med.lu.se. · Clinical Physiology and Nuclear Medicine, Lund University, Skåne University Hospital, Lund, Sweden. · Clinical Physiology and Nuclear Medicine, Lund University, Skåne University Hospital, Malmö, Sweden. ·J Nucl Cardiol · Pubmed #25500801.

ABSTRACT: -- No abstract --

11 Editorial Low degree of shared genetic susceptibility to coronary artery disease and venous thromboembolism. 2014

Zöller, Bengt. ·Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, Sweden. Electronic address: bengt.zoller@med.lu.se. ·Thromb Res · Pubmed #24985037.

ABSTRACT: -- No abstract --

12 Review Triglyceride-Rich Lipoproteins as a Source of Proinflammatory Lipids in the Arterial Wall. 2019

Öörni, Katariina / Lehti, Satu / Sjövall, Peter / Kovanen, Petri T. ·Wihuri Research Institute, Helsinki, Finland. · RISE Research Institutes of Sweden, Boras, Sweden. ·Curr Med Chem · Pubmed #29848270.

ABSTRACT: Apolipoprotein B -containing lipoproteins include triglyceride-rich lipoproteins (chylomicrons and their remnants, and very low-density lipoproteins and their remnants) and cholesterol-rich low-density lipoprotein particles. Of these, lipoproteins having sizes below 70-80 nm may enter the arterial wall, where they accumulate and induce the formation of atherosclerotic lesions. The processes that lead to accumulation of lipoprotein-derived lipids in the arterial wall have been largely studied with a focus on the low-density lipoprotein particles. However, recent observational and genetic studies have discovered that the triglyceriderich lipoproteins and their remnants are linked with cardiovascular disease risk. In this review, we describe the potential mechanisms by which the triglyceride-rich remnant lipoproteins can contribute to the development of atherosclerotic lesions, and highlight the differences in the atherogenicity between low-density lipoproteins and the remnant lipoproteins.

13 Review Coronary artery disease in post-menopausal women: are there appropriate means of assessment? 2018

Chiu, Michael H / Heydari, Bobak / Batulan, Zarah / Maarouf, Nadia / Subramanya, Vinita / Schenck-Gustafsson, Karin / O'Brien, Edward R. ·Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary Cumming School of Medicine, Calgary, AB, Canada. · Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, U.S.A. · Department of Medicine, Cardiac Unit and Centre for Gender Medicine, Karolinska Institutet, Stockholm, Sweden. · Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary Cumming School of Medicine, Calgary, AB, Canada ermobrie@ucalgary.ca. ·Clin Sci (Lond) · Pubmed #30185615.

ABSTRACT: The recognition of sex differences in cardiovascular disease, particularly the manifestations of coronary artery disease (CAD) in post-menopausal women, has introduced new challenges in not only understanding disease mechanisms but also identifying appropriate clinical means of assessing the efficacy of management strategies. For example, the majority of treatment algorithms for CAD are derived from the study of males, focus on epicardial stenoses, and inadequately account for the small intramyocardial vessel disease in women. However, newer investigational modalities, including stress perfusion cardiac magnetic resonance imaging and positron emission tomography are providing enhanced diagnostic accuracy and prognostication for women with microvascular disease. Moreover, these investigations may soon be complemented by simpler screening tools such as retinal vasculature imaging, as well as novel biomarkers (e.g. heat shock protein 27). Hence, it is vital that robust, sex-specific cardiovascular imaging modalities and biomarkers continue to be developed and are incorporated into practice guidelines that are used to manage women with CAD, as well as gauge the efficacy of any new treatment modalities. This review provides an overview of some of the sex differences in CAD and highlights emerging advances in the investigation of CAD in post-menopausal women.

14 Review Bilateral Versus Single Internal Thoracic Artery Grafts. 2018

Persson, Michael / Sartipy, Ulrik. ·Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. · Section of Cardiothoracic Surgery, Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden. · Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Ulrik.Sartipy@karolinska.se. · Section of Cardiothoracic Surgery, Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden. Ulrik.Sartipy@karolinska.se. ·Curr Cardiol Rep · Pubmed #29362968.

ABSTRACT: PURPOSE OF REVIEW: Several advances have been made in recent years to improve outcome for patients with coronary artery disease. One of the most debated topics regarding surgical treatment with coronary artery bypass grafting (CABG) is graft selection. This review aims to present the current status and scientific evidence for bilateral internal thoracic artery (BITA) grafting. RECENT FINDINGS: Observational studies and pooled analyses suggest that BITA grafting is associated with improved survival. Early results from a large randomized controlled trial report safety and efficacy of the method. The improved survival might be amplified in select groups, but with an increase in sternal wound-related complications. The benefit of BITA grafts seems to remain to an approximate age of 69 years at surgery. CABG with BITA grafts is likely associated with improved long-term survival at a cost of an increase in sternal wound infections. Ten-year results from the Arterial Revascularization Trial are expected in 2018, providing the best evidence regarding the method yet. Early results show it is a safe method in most patient categories considerable for CABG.

15 Review Culprit Vessel-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment-Elevation Myocardial Infarction: A Collaborative Meta-Analysis. 2017

Kolte, Dhaval / Sardar, Partha / Khera, Sahil / Zeymer, Uwe / Thiele, Holger / Hochadel, Matthias / Radovanovic, Dragana / Erne, Paul / Hambraeus, Kristina / James, Stefan / Claessen, Bimmer E / Henriques, Jose P S / Mylotte, Darren / Garot, Philippe / Aronow, Wilbert S / Owan, Theophilus / Jain, Diwakar / Panza, Julio A / Frishman, William H / Fonarow, Gregg C / Bhatt, Deepak L / Aronow, Herbert D / Abbott, J Dawn. ·From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.) · Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.) · Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.) · Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.) · Department of Cardiology, University Heart Center Lübeck, Medical Clinic II, University Hospital Schleswig-Holstein, Germany (H.T.) · German Cardiovascular Research Center (DZHK), Partner Site Hamburg/Kiel/Lübeck, Germany (H.T.) · AMIS Plus Data Center, University of Zurich, Switzerland (D.R., P.E.) · Department of Cardiology, Falun Hospital, Sweden (K.H.) · Department of Medical Sciences, Uppsala University, Sweden (K.H., S.J.) · Department of Cardiology, Academic Medical Center, University of Amsterdam, the Netherlands (B.E.C., J.P.S.H.) · Department of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, National University of Ireland (D.M.) · Department of Cardiology, Ramsay Générale de Santé, Institut Cardiovasculaire Paris Sud, Hopital Privé Jacques Cartier, Massy, France (P.G.) · Department of Medicine, Division of Cardiology, David-Geffen School of Medicine, University of California at Los Angeles (G.C.F.) · and Department of Medicine, Division of Cardiology, Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.). ·Circ Cardiovasc Interv · Pubmed #29146672.

ABSTRACT: BACKGROUND: The optimal revascularization strategy in patients with multivessel disease presenting with cardiogenic shock complicating ST-segment-elevation myocardial infarction remains unknown. METHODS AND RESULTS: Databases were searched from 1999 to October 2016. Studies comparing immediate/single-stage multivessel percutaneous coronary intervention (MV-PCI) versus culprit vessel-only PCI (CO-PCI) in patients with multivessel disease, ST-segment-elevation myocardial infarction, and cardiogenic shock were included. Primary end point was short-term (in-hospital or 30 days) mortality. Secondary end points included long-term mortality, cardiovascular death, reinfarction, and repeat revascularization. Safety end points were in-hospital stroke, renal failure, and major bleeding. The meta-analysis included 11 nonrandomized studies and 5850 patients (1157 MV-PCI and 4693 CO-PCI). There was no significant difference in short-term mortality with MV-PCI versus CO-PCI (odds ratio [OR], 1.08; 95% confidence interval [CI], 0.81-1.43; CONCLUSIONS: This meta-analysis of nonrandomized studies suggests that in patients with cardiogenic shock complicating ST-segment-elevation myocardial infarction, there may be no significant benefit with single-stage MV-PCI compared with CO-PCI. Given the limitations of observational data, randomized trials are needed to determine the role of MV-PCI in this setting.

16 Review Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 2017

Patrono, Carlo / Morais, Joao / Baigent, Colin / Collet, Jean-Philippe / Fitzgerald, Desmond / Halvorsen, Sigrun / Rocca, Bianca / Siegbahn, Agneta / Storey, Robert F / Vilahur, Gemma. ·Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. Electronic address: carlo.patrono@unicatt.it. · Division of Cardiology, Santo Andre's Hospital, Leiria, Portugal. · MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. · Sorbonne Université Paris 6, ACTION Study Group, Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), INSERM UMRS 1166, Paris, France. · University of Limerick, Limerick, Ireland. · Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway. · Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. · Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden. · Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom. · Cardiovascular Science Institute-ICCC IIB-Sant Pau, CiberCV, Hospital de Sant Pau, Barcelona, Spain. ·J Am Coll Cardiol · Pubmed #28958334.

ABSTRACT: Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures.

17 Review The Evolving Future of Instantaneous Wave-Free Ratio and Fractional Flow Reserve. 2017

Götberg, Matthias / Cook, Christopher M / Sen, Sayan / Nijjer, Sukhjinder / Escaned, Javier / Davies, Justin E. ·Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden. Electronic address: Matthias.gotberg@med.lu.se. · Hammersmith Hospital, Imperial College London, London, United Kingdom. · Hospital Clínico San Carlos, Madrid, Spain. ·J Am Coll Cardiol · Pubmed #28882237.

ABSTRACT: In this review, the authors reflect upon the role of coronary physiology in the modern management of coronary artery disease. They critically appraise the scientific background of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR), from early experimental studies to validation studies against indexes of ischemia, to clinical trials assessing outcome. At this important juncture for the field, the authors make predictions for the future of physiological stenosis assessment, outlining developments for both iFR and FFR in new clinical domains beyond the confines of stable angina. With a focus on the evolving future of iFR and FFR, the authors describe how physiological assessment with iFR may advance its application from simply justifying to guiding revascularization.

18 Review Impact of Sex on Cardiac Troponin Concentrations-A Critical Appraisal. 2017

Eggers, Kai M / Lindahl, Bertil. ·Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. kai.eggers@ucr.uu.se. · Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. ·Clin Chem · Pubmed #28630238.

ABSTRACT: BACKGROUND: The use of sex-specific cutoffs for cardiac troponin (cTn) is currently debated. Although endorsed by scientific working groups, concerns have been raised that sex-specific cutoffs may have only a small clinical effect at the cost of increased complexity in decision-making. METHODS: We reviewed studies investigating the interrelations between high-sensitivity (hs) cTn results and sex, diagnoses, and outcome. Investigated populations included community-dwelling subjects and patients with stable angina, congestive heart failure, or acute chest pain including those with acute coronary syndromes. RESULTS: Men usually have higher hs-cTn concentrations compared with women, regardless of the assessed population or the applied assay. The distribution and prognostic implications of hs-cTn concentrations indicate that women have a broader cardiovascular risk panorama compared with men, particularly at lower hs-cTn concentrations. At higher concentrations, particularly above the 99th percentile, this variation is often attenuated. Sex-specific hs-cTn 99th percentiles have so far shown clinical net benefit in only 1 study assessing patients with chest pain. However, several methodological aspects need to be considered when interpreting study results, e.g., issues related to the determination of the 99th percentiles, the selection bias, and the lack of prospective and sufficiently powered analyses. CONCLUSIONS: Available studies do not show a consistent clinical superiority of sex-specific hs-cTn 99th percentiles. This may reflect methodological aspects. However, from a pathobiological perspective, the use of sex-specific hs-cTn 99th percentiles makes sense for the ruling in of myocardial infarction. We propose a new approach to hs-cTn 99th cutoffs taking into account the analytical properties of the used assays.

19 Review Recent Advances in Cardiovascular Magnetic Resonance: Techniques and Applications. 2017

Salerno, Michael / Sharif, Behzad / Arheden, Håkan / Kumar, Andreas / Axel, Leon / Li, Debiao / Neubauer, Stefan. ·From the Cardiovascular Division, Department of Medicine, Department of Radiology and Medical Imaging, and Department of Biomedical Engineering, University of Virginia Health System, Charlottesville (M.S.) · Biomedical Imaging Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA (B.S., D.L.) · Department of Clinical Sciences, Clinical Physiology, Lund University, Skane University Hospital, Sweden (H.A.) · Cardiology Division, Department of Medicine, Northern Ontario School of Medicine, Sudbury, Canada (A.K.) · Department of Radiology and Department of Medicine, New York University, New York (L.A.) · and Division of Cardiovascular Medicine, Oxford Center for Clinical Magnetic Resonance Research, University of Oxford, London, United Kingdom (S.N.). ·Circ Cardiovasc Imaging · Pubmed #28611116.

ABSTRACT: Cardiovascular magnetic resonance imaging has become the gold standard for evaluating myocardial function, volumes, and scarring. Additionally, cardiovascular magnetic resonance imaging is unique in its comprehensive tissue characterization, including assessment of myocardial edema, myocardial siderosis, myocardial perfusion, and diffuse myocardial fibrosis. Cardiovascular magnetic resonance imaging has become an indispensable tool in the evaluation of congenital heart disease, heart failure, cardiac masses, pericardial disease, and coronary artery disease. This review will highlight some recent novel cardiovascular magnetic resonance imaging techniques, concepts, and applications.

20 Review Systematic review of cost-effectiveness of myocardial perfusion scintigraphy in patients with ischaemic heart disease: A report from the cardiovascular committee of the European Association of Nuclear Medicine. Endorsed by the European Association of Cardiovascular Imaging. 2017

Trägårdh, Elin / Tan, Siok Swan / Bucerius, Jan / Gimelli, Alessia / Gaemperli, Oliver / Lindner, Oliver / Agostini, Denis / Übleis, Christopher / Sciagrà, Roberto / Slart, Riemer H / Underwood, S Richard / Hyafil, Fabien / Hacker, Marcus / Verberne, Hein J. ·Clinical Physiology and Nuclear Medicine, Lund University and Skåne University Hospital, Inga Marie Nilssons gata 49, 205 02 Malmö, Sweden. · Erasmus University Rotterdam, Institute for Medical Technology Assessment, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands. · Department of Nuclear Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, PO Box 5800, 6202 AZ, Maastricht, The Netherlands. · Department of Nuclear Medicine, University Hospital, Pauwelsstrasse 30, 52074 Aachen, Germany. · Fondazione Toscana Gabriele Monasterio, Via Guiseppe Moruzzi 1, 56124 Pisa, Italy. · Cardiac Imaging and Interventional Cardiology, University Heart Centre, Rämistrasse 100, 8091 Zurich, Switzerland. · Institute of Radiology, Nuclear Medicine and Molecular Imaging, Heart and Diabetes Centre North Rhine-Westphalia, University Hospital of the Ruhr University Bochum, Georgstrasse 11, 32545 Bad Oeynhausen, Germany. · Department of Nuclear Medicine, University Hospital of Caen and Normandie Université, Avenue de la Côte de Nacre, 104009 CEDEX 1 Caen, France. · Department of Clinical Radiology, Ludwig-Maximilians Universität München, Marchioninistrasse 15, 81377 Munich, Germany. · Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Largo Brambilla 3, 50134 Florence, Italy. · Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB, Groningen, The Netherlands. · Department of Biomedical Photonic Imaging, University of Twente, PO Box 217, 7500 AE, Enschede, The Netherlands. · National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield Hospitals, Sydney Street, SW3 6NP, London, UK. · Department of Nuclear Medicine, Bichat University Hospital, DHU FIRE, Inserm 1148, University of Paris Diderot, 46 rue Henri Huchard, 75018 Paris, France. · Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. · Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. ·Eur Heart J Cardiovasc Imaging · Pubmed #28549119.

ABSTRACT: Coronary artery disease (CAD) is a major cause of death and disability. Several diagnostic tests, such as myocardial perfusion scintigraphy (MPS), are accurate for the detection of CAD, as well as having prognostic value for the prediction of cardiovascular events. Nevertheless, the diagnostic and prognostic value of these tests should be cost-effective and should lead to improved clinical outcome. We have reviewed the literature on the cost-effectiveness of MPS in different circumstances: (i) the diagnosis and management of CAD; (ii) comparison with exercise electrocardiography (ECG) and other imaging tests; (iii) as gatekeeper to invasive coronary angiography (ICA), (iv) the impact of appropriate use criteria; (v) acute chest pain, and (vi) screening of asymptomatic patients with type-2 diabetes. In total 57 reports were included. Although most non-invasive imaging tests are cost-effective compared with alternatives, the data conflict on which non-invasive strategy is the most cost-effective. Different definitions of cost-effectiveness further confound the subject. Computer simulations of clinical diagnosis and management are influenced by the assumptions made. For instance, diagnostic accuracy is often defined against an anatomical standard that is wrongly assumed to be perfect. Conflicting data arise most commonly from these incorrect or differing assumptions.

21 Review Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. 2017

Costa, Francesco / van Klaveren, David / James, Stefan / Heg, Dik / Räber, Lorenz / Feres, Fausto / Pilgrim, Thomas / Hong, Myeong-Ki / Kim, Hyo-Soo / Colombo, Antonio / Steg, Philippe Gabriel / Zanchin, Thomas / Palmerini, Tullio / Wallentin, Lars / Bhatt, Deepak L / Stone, Gregg W / Windecker, Stephan / Steyerberg, Ewout W / Valgimigli, Marco / Anonymous4670899. ·Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland; Erasmus University Medical Center, Rotterdam, Netherlands; Department of Clinical and Experimental Medicine, Policlinic "G Martino", University of Messina, Messina, Italy. · Erasmus University Medical Center, Rotterdam, Netherlands; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA. · Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. · Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. · Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland. · Istituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil. · Severance Cardiovascular Hospital, Yonsei University College of Medicine and Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea. · Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. · EMO-GVM Centro Cuore Columbus, Milan, Italy; Interventional Cardiology Department, San Raffaele Scientific Institute, Milan, Italy. · Department of Cardiology, Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, Paris, France. · Dipartimento Cardio-Toraco-Vascolare, University of Bologna, Bologna, Italy. · Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA, USA. · Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA. · Erasmus University Medical Center, Rotterdam, Netherlands. · Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland; Erasmus University Medical Center, Rotterdam, Netherlands. Electronic address: marco.valgimigli@insel.ch. ·Lancet · Pubmed #28290994.

ABSTRACT: BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y METHODS: A total of 14 963 patients treated with DAPT after coronary stenting-largely consisting of aspirin and clopidogrel and without indication to oral anticoagulation-were pooled at a single-patient level from eight multicentre randomised clinical trials with independent adjudication of events. Using Cox proportional hazards regression, we identified predictors of out-of-hospital Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding stratified by trial, and developed a numerical bleeding risk score. The predictive performance of the novel score was assessed in the derivation cohort and validated in patients treated with percutaneous coronary intervention from the PLATelet inhibition and patient Outcomes (PLATO) trial (n=8595) and BernPCI registry (n=6172). The novel score was assessed within patients randomised to different DAPT durations (n=10 081) to identify the effect on bleeding and ischaemia of a long (12-24 months) or short (3-6 months) treatment in relation to baseline bleeding risk. FINDINGS: The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, white-blood-cell count, and previous spontaneous bleeding) showed a c-index for out-of-hospital TIMI major or minor bleeding of 0·73 (95% CI 0·61-0·85) in the derivation cohort, and 0·70 (0·65-0·74) in the PLATO trial validation cohort and 0·66 (0·61-0·71) in the BernPCI registry validation cohort. A longer DAPT duration significantly increased bleeding in patients at high risk (score ≥25), but not in those with lower risk profiles (p INTERPRETATION: The PRECISE-DAPT score is a simple five-item risk score, which provides a standardised tool for the prediction of out-of-hospital bleeding during DAPT. In the context of a comprehensive clinical evaluation process, this tool can support clinical decision making for treatment duration. FUNDING: None.

22 Review Role of PVAT in coronary atherosclerosis and vein graft patency: friend or foe? 2017

Fernández-Alfonso, M S / Gil-Ortega, M / Aranguez, I / Souza, D / Dreifaldt, M / Somoza, B / Dashwood, M R. ·Instituto Pluridisciplinar and Facultad de Farmacia, Universidad Complutense, Madrid, Spain. · Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad CEU-San Pablo, Madrid, Spain. · Department of Cardiothoracic and Vascular Surgery and University Health Care Research Center, School of Medical Sciences, Örebro University, Örebro, Sweden. · Royal Free Hospital Campus, University College Medical School, London, UK. ·Br J Pharmacol · Pubmed #28150299.

ABSTRACT: Perivascular adipose tissue (PVAT) releases numerous factors and adipokines with paracrine effects on both vascular structure and function. These effects are variable as they depend on regional differences in PVAT among blood vessels and vary with changes in adiposity. There is considerable evidence demonstrating an association between coronary PVAT and the development and progression of coronary artery disease, which is associated with inflammation, oxidative stress, angiogenesis, vascular remodelling and blood clotting. However, PVAT also has a protective role in vascular grafts, especially the no-touch saphenous vein, in patients undergoing coronary artery bypass. This beneficial influence of PVAT involves factors such as adipocyte-derived relaxing factor, nitric oxide (NO), leptin, adiponectin, prostanoids, hydrogen sulphide and neurotransmitters, as well as mechanical protection. This article aims to highlight and compare the dual role of PVAT in the development and progression of coronary atherosclerosis, as well as in increased graft patency. Different deleterious and protective mechanisms of PVAT are also discussed and the inside-outside signalling paradigm of atherosclerosis development re-evaluated. The bidirectional communication between the arterial and venous wall and their surrounding PVAT, where signals originating from the vascular wall or lumen can affect PVAT phenotype, has been shown to be very complex. Moreover, signals from PVAT also influence the structure and function of the vascular wall in a paracrine manner. LINKED ARTICLES: This article is part of a themed section on Molecular Mechanisms Regulating Perivascular Adipose Tissue - Potential Pharmacological Targets? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.20/issuetoc.

23 Review Coronary Artery Fistulas: Case Series and Literature Review. 2017

Karazisi, Christina / Eriksson, Peter / Dellborg, Mikael. ·Section of Cardiology, Department of Medicine, Sahlgrenska University Hospital, Östra, Gothenburg, Sweden. ·Cardiology · Pubmed #27577264.

ABSTRACT: Congenital coronary artery fistulas are rare anomalies. As coronary angiography and multidetector computed tomography have become more accessible, they have been increasingly used in the investigation of chest pain and heart failure. Coronary artery fistulas are often an incidental finding, which raises the question of how patients with this condition should be managed. Intervention with either transcatheter closure or surgical closure is often technically possible. Many patients are asymptomatic early after closure. However, follow-up studies have shown post-closure sequelae, such as residual leakage, thrombosis with or without myocardial infarction, and coronary stenosis. Therefore, there has been a shift from intervention towards watchful waiting in asymptomatic patients. In this article, we review the published literature on the natural history and treatment outcomes in individuals with coronary artery fistulas. We present case reports from our clinic and discuss the management of incidental findings of coronary artery fistulas.

24 Review Common genetic risk factors for coronary artery disease: new opportunities for prevention? 2017

Hamrefors, Viktor. ·Department of Clinical Sciences, Faculty of Medicine, Lund University, Malmö, Sweden. · Department of Medical Imaging and Physiology, Skåne University Hospital, Malmö, Sweden. ·Clin Physiol Funct Imaging · Pubmed #26278888.

ABSTRACT: Atherosclerotic cardiovascular disease (CVD) is a leading cause of mortality and morbidity worldwide, with coronary artery disease (CAD) being the single leading cause of death. Better control of risk factors, enhanced diagnostic techniques and improved medical therapies have all substantially decreased the mortality of CAD in developed countries. However, CAD and other forms of atherosclerotic CVD are projected to remain the leading cause of death by 2030 and we face a number of challenges if the outcomes of CAD are to be further improved. The fact that a substantial fraction of high-risk subjects do not reach treatment goals for important risk factors is one of these challenges. At the same time, there is also a non-negotiable fraction of 'concealed' high-risk subjects who are not detected by current risk algorithms and diagnostic modalities. In recent years, we have started to rapidly increase our knowledge of the framework of common genetics underlying CAD and atherosclerotic CVD in the population. In conjunction with modern diagnostic and therapeutic options, this new genetic knowledge may provide a valuable tool for further improvements in prevention. This review summarizes the recent findings from the search for common genetic risk factors for CAD. Furthermore, the author discusses how such recent findings could potentially be used in a number of clinical applications within CAD prevention, including in clinical risk stratification, in prediction of drug treatment response and in the search for targets for novel preventive therapies.

25 Review Percutaneous Coronary Intervention for Bifurcation Lesions. 2016

Redfors, Björn / Généreux, Philippe. ·Clinical Trial Center, Cardiovascular Research Foundation, 111 East 59th Street, New York, NY 10022, USA; Department of Cardiology, Sahlgrenska University Hospital, Bruna Straket 16, 413 45 Gothenburg, Sweden. · Clinical Trial Center, Cardiovascular Research Foundation, 111 East 59th Street, New York, NY 10022, USA; Department of Cardiology, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, 5400, boul. Gouin Ouest, Montréal, Québec H4J 1C5, Canada. Electronic address: pgenereux@crf.org. ·Interv Cardiol Clin · Pubmed #28582201.

ABSTRACT: This article summarizes treatment alternatives for coronary bifurcation lesions. It also reviews current definitions and classifications pertaining to bifurcation lesions and provides an overview of the impact of bifurcation lesions on clinical outcomes.

Next